https://doi.org/10.55788/ab33f531
The first-line treatment for EBV-associated R/M NPC is gemcitabine plus carboplatin [1]. EBV-CTL is an autologous T-cell immunotherapy generated from patients’ blood that has shown promising efficacy in combination with standard first-line chemotherapy in patients with R/M NPC [2].
The VANCE trial (NCT02578641) evaluated the efficacy and safety of gemcitabine plus carboplatin followed by EBV-CTL versus gemcitabine plus carboplatin alone. Dr Han Chong Toh (National Cancer Centre, Singapore) presented the first results [3].
A total of 330 patients were enrolled in 5 countries worldwide (R/M NPC predominantly occurs in people with (South East) Asian ethnicity) and 1:1 randomised to receive 6 cycles of chemotherapy alone (1,000 mg/m2 gemcitabine, AUC 2 carboplatin on days 1 and 8) or 4 cycles of chemotherapy followed by up to 6 cycles of EBV-CTL. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety.
The median OS did not differ significantly between the 2 treatment arms: 25.0 months in the chemotherapy plus EBV-CTL arm versus 24.9 months in the chemotherapy alone arm (HR 1.19; P=0.942). However, there was a trend towards improved OS in patients from USA, Taiwan, and Singapore. The addition of EBV-CTL to the standard chemotherapy regimen did not improve median PFS or ORR. The safety profile was identical in both treatment arms.
“EBV-CTL treatment is well tolerated, but does not improve survival in patients with R/M NPC,” concluded Dr Toh.
- Bossi P, et al. Ann Oncol. 2020;32(4):452–465.
- Chia W-K, et al. Mol Ther. 2014;22(1):132–139.
- Toh HC, et al. Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC). Abstract 652O, ESMO Congress 2022, 09–13 September, Paris, France.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« OS benefit for advanced ovarian cancer patients treated with maintenance olaparib Next Article
5-FU-free chemotherapy combination as an alternative for first-line treatment of recurrent or metastatic HNSCC »
« OS benefit for advanced ovarian cancer patients treated with maintenance olaparib Next Article
5-FU-free chemotherapy combination as an alternative for first-line treatment of recurrent or metastatic HNSCC »
Table of Contents: ESMO 2022
Featured articles
Letter from the Editor
Colorectal Cancer
High pathological responses to neoadjuvant immune checkpoint inhibition in locally advanced dMMR colon cancer
Fruquintinib: a potential new treatment for patients with refractory mCRC
Second-line avelumab is effective in patients with MSI-H/dMMR mCRC
Upper Gastrointestinal Cancer
Deep learning models predict the risk of relapse and the mutational profile in GIST
Addition of pembrolizumab to lenvatinib does not improve OS in advanced HCC
New, highly selective inhibitor of FGFR2 driver alterations and resistance mutations
Chemo-immunotherapy in gastric cancer is more effective when administered in parallel
Breast Cancer
Tumour infiltrating lymphocytes identify patients with immunogenic triple-negative breast cancer
OS benefit of abemaciclib in HR-positive/HER2-negative advanced breast cancer not (yet) statistically significant
OS benefit of sacituzumab govitecan in pre-treated HR-positive/HER2-negative metastatic breast cancer
Lung Cancer
A pathway from air pollution to lung cancer in non-smokers identified
Selective KRASG12C inhibitor sotorasib demonstrates superior PFS and ORR compared to docetaxel in previously treated patients with NSCLC
Promising clinical activity of tepotinib plus osimertinib in NSCLC with MET amplification after progression on first-line osimertinib
High pathological responses in borderline resectable NSCLC patients after induction with dual immunotherapy and concurrent chemoradiotherapy
Melanoma
Treatment with tumour-infiltrating lymphocytes for advanced melanoma outperforms ipilimumab
Neoadjuvant pembrolizumab outperforms adjuvant pembrolizumab in resectable stage III–IV melanomas
Survival-benefit of neoadjuvant T-VEC maintained over 5 years of follow-up
Baseline ctDNA predicts survival in resected stage III–IV melanoma
Genitourinary Cancer – Prostate Cancer
Overall survival benefit of abiraterone in mHSPC is maintained for 7 years
Limited benefit of adding long-term ADT to post-operative radiotherapy in prostate cancer
Intensified ADT benefits biochemical progression-free survival in biochemically relapsed prostate cancer
Genitourinary Cancer – Non-Prostate Cancer
Adjuvant nivolumab plus ipilimumab does not improve survival in patients with localised RCC at high risk of relapse after nephrectomy
Triple therapy improves progression-free survival in patients with advanced RCC versus dual therapy
Adjuvant atezolizumab does not improve outcomes for patients with RCC and increased risk of recurrence
Gynaecological cancers
OS benefit for advanced ovarian cancer patients treated with maintenance olaparib
Maintenance tegafur-uracil does not improve survival in locally advanced cervical cancer
Head and Neck Cancer
Adding first-line pembrolizumab to CRT in locally advanced HNSCC does not significantly prolong survival or event-free survival
5-FU-free chemotherapy combination as an alternative for first-line treatment of recurrent or metastatic HNSCC
Epstein Barr virus-specific autologous cytotoxic T lymphocytes do not improve survival in nasopharyngeal carcinoma
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com